Mass Spectrometry & Spectroscopy

  • Can Llama Antibodies Fight Against COVID-19?

Can Llama Antibodies Fight Against COVID-19?

Jan 20 2021 Read 13368 Times

In a novel twist for COVID-19 research, a team of neuroscientists from the NIH/National Institute of Neurological Disorders and Stroke has uncovered data suggesting llama antibodies could be used to prevent and diagnose human infections. The team managed to isolate tiny 'nanobodies’ produced by a laboratory llama named Cormac, with preliminary results suggesting a particular single-domain fragment known as NIH-CoVnb-112 could be used to latch onto SARS-CoV-2 spike proteins and prevent infection.

From brain imaging to epidemiology  

Findings were published in the journal Scientific Reports, with senior author David L. Brody saying the study is an exciting step forward for COVID-19 research. “For years TJ and I had been testing out how to use nanobodies to improve brain imaging. When the pandemic broke, we thought this was a once in a lifetime, all-hands-on-deck situation and joined the fight," says Brody. "We hope that these anti-COVID-19 nanobodies may be highly effective and versatile in combating the coronavirus pandemic.”

Inspired by the immune systems of camelids

Naturally produced by camelid immune systems, nanobodies are found in llamas, camels, alpacas and other members of the Camelidae family. The compact and lightweight proteins weight around one tenth of human antibodies and resemble the arm ‘tips’ of heavy chain proteins that support Y-shaped human IgG antibodies. These tips play an important role in identifying viral and bacterial proteins and protecting the body against such antigens.  

As well as being more stable than antibodies, camelid nanobodies are also easier and cheaper to produce. As a result, they have gained popularity in medical research laboratories around the world. Now, they’re being used to combat one of the deadliest viral outbreaks of the century.

Closing the door to infection

To harvest antibodies the team immunised Cormac with the SARS-CoV-2 spike protein five times over a 28-day period. They then tested hundreds of antibodies and identified several with promising defensive properties. Candidates included NIH-CoVnb-112, which bound to the ACE2 receptor with up to 10 times more strength than other lab-produced nanobodies.

"The SARS-CoV-2 spike protein acts like a key. It does this by opening the door to infections when it binds to a protein called the angiotensin converting enzyme 2 (ACE2) receptor, found on the surface of some cells," explains lead author of the study Thomas J. "T.J." Esparza. "We developed a method that would isolate nanobodies that block infections by covering the teeth of the spike protein that bind to and unlock the ACE2 receptor.”

Moving forward the team hope to explore the promising results and potentially use llama nanobodies to develop safe and effective treatments for SARS-CoV-2. Find out more about the latest scientific advancements in ‘Benchtop NMR – Bringing New Access to Technology to the Next Generation of Scientists.'

Digital Edition

International Labmate February 2021

February 2021

In This Edition Articles - Expanding the Boundaries of Light Scattering for Macromolecules - Electrostatic Charges and Their Effects on Weighing - How the world’s most advanced analytical...

View all digital editions


IFPAC Annual Meeting

Feb 28 2021 Virtual event

SIAF Guangzhou

Mar 03 2021 Guanghzou, China


Mar 08 2021 Virtual Event

Bio-Europe Spring

Mar 22 2021 Digital event

Medtec Japan 2021

Apr 14 2021 Tokyo, Japan

View all events